PE20170313A1 - Formulacion de ceritinib - Google Patents

Formulacion de ceritinib

Info

Publication number
PE20170313A1
PE20170313A1 PE2016002399A PE2016002399A PE20170313A1 PE 20170313 A1 PE20170313 A1 PE 20170313A1 PE 2016002399 A PE2016002399 A PE 2016002399A PE 2016002399 A PE2016002399 A PE 2016002399A PE 20170313 A1 PE20170313 A1 PE 20170313A1
Authority
PE
Peru
Prior art keywords
ceritinib
composition
binder
refers
granules
Prior art date
Application number
PE2016002399A
Other languages
English (en)
Spanish (es)
Inventor
Simon Ensslin
Sebastien Breulles
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20170313A1 publication Critical patent/PE20170313A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
PE2016002399A 2014-05-29 2015-05-27 Formulacion de ceritinib PE20170313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
PE20170313A1 true PE20170313A1 (es) 2017-04-18

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002399A PE20170313A1 (es) 2014-05-29 2015-05-27 Formulacion de ceritinib

Country Status (27)

Country Link
US (4) US20170112834A1 (cg-RX-API-DMAC7.html)
EP (1) EP3148513B1 (cg-RX-API-DMAC7.html)
JP (3) JP6679578B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170008239A (cg-RX-API-DMAC7.html)
CN (1) CN106456640B (cg-RX-API-DMAC7.html)
AR (1) AR100625A1 (cg-RX-API-DMAC7.html)
AU (3) AU2015265470A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016027580A8 (cg-RX-API-DMAC7.html)
CA (1) CA2948291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016003047A1 (cg-RX-API-DMAC7.html)
DK (1) DK3148513T3 (cg-RX-API-DMAC7.html)
EA (1) EA036922B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16096826A (cg-RX-API-DMAC7.html)
ES (1) ES2792574T3 (cg-RX-API-DMAC7.html)
HU (1) HUE048950T2 (cg-RX-API-DMAC7.html)
IL (1) IL248835B (cg-RX-API-DMAC7.html)
MX (1) MX373624B (cg-RX-API-DMAC7.html)
PE (1) PE20170313A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016502272A1 (cg-RX-API-DMAC7.html)
PL (1) PL3148513T3 (cg-RX-API-DMAC7.html)
PT (1) PT3148513T (cg-RX-API-DMAC7.html)
SG (1) SG11201609208UA (cg-RX-API-DMAC7.html)
SI (1) SI3148513T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000484A1 (cg-RX-API-DMAC7.html)
TW (1) TWI721946B (cg-RX-API-DMAC7.html)
UY (1) UY36140A (cg-RX-API-DMAC7.html)
WO (1) WO2015181739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948291A1 (en) 2014-05-29 2015-12-03 Novartis Ag Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
EP1993516A2 (en) * 2006-03-06 2008-11-26 Wyeth Tablet formulations and processes
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
WO2008073687A2 (en) 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2311807B1 (en) * 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
SI2334202T1 (sl) 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2467029A1 (en) 2009-08-18 2012-06-27 Cargill, Incorporated Tabletting of erythritol and isomalt
WO2011142478A1 (en) 2010-05-11 2011-11-17 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
EP2613645A1 (en) 2010-09-07 2013-07-17 Cargill, Incorporated Solidified sugar alcohol mixture
CA2948291A1 (en) 2014-05-29 2015-12-03 Novartis Ag Ceritinib formulation

Also Published As

Publication number Publication date
AU2015265470A1 (en) 2016-11-24
MX2016015736A (es) 2017-03-16
EA036922B1 (ru) 2021-01-15
AU2019232937B2 (en) 2020-10-15
JP2022078236A (ja) 2022-05-24
TWI721946B (zh) 2021-03-21
AU2018203007B2 (en) 2019-07-18
US20200009141A1 (en) 2020-01-09
JP7084955B2 (ja) 2022-06-15
JP2017520619A (ja) 2017-07-27
US20190022095A1 (en) 2019-01-24
CL2016003047A1 (es) 2017-04-07
WO2015181739A1 (en) 2015-12-03
US20170112834A1 (en) 2017-04-27
ECSP16096826A (es) 2018-04-30
MX373624B (es) 2020-05-22
BR112016027580A8 (pt) 2021-06-29
TN2016000484A1 (en) 2018-04-04
EP3148513B1 (en) 2020-02-26
US20210154194A1 (en) 2021-05-27
PL3148513T3 (pl) 2020-08-24
CN106456640B (zh) 2021-05-14
BR112016027580A2 (pt) 2017-08-15
JP6679578B2 (ja) 2020-04-15
EA201692310A1 (ru) 2017-04-28
DK3148513T3 (da) 2020-05-25
SI3148513T1 (sl) 2020-07-31
TW201613580A (en) 2016-04-16
US12357630B2 (en) 2025-07-15
KR20170008239A (ko) 2017-01-23
EP3148513A1 (en) 2017-04-05
HUE048950T2 (hu) 2020-09-28
AR100625A1 (es) 2016-10-19
PH12016502272A1 (en) 2017-02-06
SG11201609208UA (en) 2016-12-29
AU2018203007A1 (en) 2018-05-17
CN106456640A (zh) 2017-02-22
IL248835B (en) 2020-05-31
PT3148513T (pt) 2020-05-27
UY36140A (es) 2016-01-08
US11000523B2 (en) 2021-05-11
JP2020114834A (ja) 2020-07-30
ES2792574T3 (es) 2020-11-11
AU2019232937A1 (en) 2019-10-10
CA2948291A1 (en) 2015-12-03
IL248835A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
NZ728392A (en) High dosage strength tablets of rucaparib
MX372673B (es) Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015001358A1 (es) Potenciadores del cftr deuterados
CL2016001895A1 (es) Compuestos
CU20130033A7 (es) Imidazopiridazinas sustituidas
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
AR107392A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
MX2018004664A (es) Antagonistas de ep4.
PE20180036A1 (es) Inhibidores de bromodominio
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer

Legal Events

Date Code Title Description
FD Application declared void or lapsed